Target intelligence / Profile preview

Cancer-Testis Antigens (CTA) and Oncofetal Antigens (OFA) (CTA/OFA)

Target
CTA/OFA
Molecular classification
Tumor-associated antigen, Cancer-testis antigen, Oncofetal protein
01

Overview

Retired self-proteins refers to a class of tumor-associated antigens, primarily Cancer-Testis Antigens (CTAs) and Oncofetal Antigens, which are normally expressed during embryonic development or in germ cells but are silenced in healthy adult tissues (Gnjatic et al., 2006; StatPearls). In ovarian cancer, these proteins are frequently re-expressed due to epigenetic dysregulation, making them ideal targets for immunotherapy as the immune system perceives them as foreign in the context of adult somatic tissue (Thomas et al., 2023). These antigens are considered self-proteins because they are encoded by the host genome, but they are retired in the sense that their physiological expression is restricted to specific developmental windows (OSE Immunotherapeutics). Therapeutic strategies targeting these proteins, such as the neoepitope vaccine Tedopi (OSE-2101), utilize specific peptide sequences to prime cytotoxic T-lymphocytes to recognize and destroy cancer cells (OSE Immunotherapeutics). Because these proteins are generally absent from vital adult organs, they offer a wide therapeutic window with a low risk of systemic autoimmunity (NCI). However, the primary challenge in targeting these proteins is the heterogeneity of their expression within the tumor, which can lead to immune evasion and treatment resistance (Thomas et al., 2023).

Other names
Retired self-proteinsCancer-testis antigensOncofetal antigensTumor-associated antigensTAAsNeoepitopes
02

Mechanism of action

Induction of a multi-epitope cytotoxic T-lymphocyte (CTL) response against tumor cells re-expressing developmental or germline-specific proteins.

03

Biological functions

Germ cell developmentEmbryogenesisCell proliferationEpigenetic regulation
04

Disease associations

Ovarian cancerNon-small cell lung cancerMelanomaSolid tumors
05

Safety considerations

Antigenic escapeIntra-tumoral heterogeneityPotential for low-level expression in non-target tissues
06

Interacting drugs

Tedopi (OSE-2101)

2 more in the full profile.

07

Biomarkers

HLA-A2 statusMAGE-A3 expressionNY-ESO-1 expressionCEA expressionP53 mutation status

Beyond the preview

Go deeper on Cancer-Testis Antigens (CTA) and Oncofetal Antigens (OFA) (CTA/OFA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cancer-Testis Antigens (CTA) and Oncofetal Antigens (OFA) (CTA/OFA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call